Peripheral CD4+ CD25+ Treg cell expansion in lung transplant recipients is not affected by calcineurin inhibitors

2006 ◽  
Vol 6 (13-14) ◽  
pp. 2002-2010 ◽  
Author(s):  
F. Meloni ◽  
M. Morosini ◽  
N. Solari ◽  
F. Bini ◽  
P. Vitulo ◽  
...  
Keyword(s):  
Treg Cell ◽  
Cell Expansion ◽  
Lung Transplant ◽  
Calcineurin Inhibitors ◽  
Transplant Recipients ◽  
Lung Transplant Recipients

scholarly journals A Retrospective Review of Calcineurin Inhibitors’ Impact on Cytomegalovirus Infections in Lung Transplant Recipients

2021 ◽  
Vol 2 (4) ◽  
pp. 478-490
Author(s):  
Rita Nogueiras-Álvarez ◽  
Víctor Manuel Mora-Cuesta ◽  
José Manuel Cifrián Martínez ◽  
María Ángeles de Cos Cossío ◽  
María del Mar García Sáiz
Keyword(s):  
Retrospective Review ◽  
Allograft Rejection ◽  
Lung Transplant ◽  
Calcineurin Inhibitors ◽  
Blood Levels ◽  
Transplant Recipients ◽  
Cmv Infection ◽  
Related Factors ◽  
Significant Difference ◽  
Lung Transplant Recipients

Immunosuppressive therapy reduces the risk for allograft rejection but leaves recipients susceptible to infections. Cytomegalovirus (CMV) is one of the most frequent causes for infection after transplantation and increases the risk for allograft rejection. As lung transplant recipients (LTRs) need to be under immunosuppression for life, they are a vulnerable group. To determine the potential association between the development of CMV infection and the calcineurin inhibitor (CNI) blood levels within previous 90 days, a retrospective review of LTRs was performed. Data from recipients who underwent a lung transplantation (LTx) at our center from January 2011 to December 2018 were collected. The studied recipients, after case/control matching, included 128 CMV-infection cases. The median time from the transplant to the first positive CMV viral load was 291.5 days. In our study, more patients were treated with tacrolimus (91.9%) than with cyclosporine (8.1%). Drug blood levels at selected timepoints showed no statistically significant difference between cases and controls. However, we found that CMV infection was more frequent in the donor-seropositive/recipient-seronegative group, interstitial lung disease (ILD) recipients, LTRs who underwent basiliximab induction, cyclosporine treated recipients, and LTRs with lymphopenia (at the time of CMV infection and 90 days before). In this review of LTRs, no association between the CNI blood level and CMV infection was seen, although other immunity-related factors were found to be influencing, i.e., basiliximab induction, cyclosporine treatment, and lymphopenia.

Sign in / Sign up

Export Citation Format

Share Document